Louis De Mestier

Louis De Mestier

Clichy-sous-bois, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 151 publications

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

Journal: Journal of neuroendocrinology

Published: March 20, 2026

Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm.

Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm.

Journal: Clinical and translational gastroenterology

Published: March 19, 2026

Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study.

Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study.

Journal: Surgical endoscopy

Published: February 27, 2026

Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM).

Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM).

Journal: Cancer letters

Published: January 23, 2026

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Journal: Lancet (London, England)

Published: December 04, 2025

Clinical and Pathological Features of EC-cell Familial Small Intestine Neuroendocrine Tumors: A Nationwide Cohort From the French GTE-RENATEN Network.

Clinical and Pathological Features of EC-cell Familial Small Intestine Neuroendocrine Tumors: A Nationwide Cohort From the French GTE-RENATEN Network.

Journal: Endocrine pathology

Published: November 17, 2025

Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.

Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.

Journal: Endocrine pathology

Published: September 13, 2025

Chemoembolization using streptozotocin versus embolization in metastatic NETs.

Chemoembolization using streptozotocin versus embolization in metastatic NETs.

Journal: Endocrine-related cancer

Published: August 05, 2025

Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients.

Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients.

Journal: Therapeutic advances in medical oncology

Published: August 02, 2025

Molecular alterations in high-grade neuroendocrine tumors of the small intestine.

Molecular alterations in high-grade neuroendocrine tumors of the small intestine.

Journal: The Journal of pathology

Published: June 06, 2025

Performance of Immunohistochemistry to Detect Rb/p53 Alterations in High-Grade Neuroendocrine Neoplasms: Staining Patterns and Comparison with Genetic Testing.

Performance of Immunohistochemistry to Detect Rb/p53 Alterations in High-Grade Neuroendocrine Neoplasms: Staining Patterns and Comparison with Genetic Testing.

Journal: Endocrine pathology

Published: June 05, 2025

Showing 1-12 of 151

Last Updated: 09/26/2026